Success Metrics

Clinical Success Rate
76.9%

Based on 10 completed trials

Completion Rate
77%(10/13)
Active Trials
0(0%)
Results Posted
50%(5 trials)
Terminated
3(21%)

Phase Distribution

Ph early_phase_1
1
7%
Ph phase_3
1
7%
Ph phase_1
4
29%
Ph phase_2
7
50%
Ph phase_4
1
7%

Phase Distribution

5

Early Stage

7

Mid Stage

2

Late Stage

Phase Distribution14 total trials
Early Phase 1First-in-human
1(7.1%)
Phase 1Safety & dosage
4(28.6%)
Phase 2Efficacy & side effects
7(50.0%)
Phase 3Large-scale testing
1(7.1%)
Phase 4Post-market surveillance
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(10)
Terminated(3)
Other(1)

Detailed Status

Completed10
Terminated3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
76.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.1%)
Phase 14 (28.6%)
Phase 27 (50.0%)
Phase 31 (7.1%)
Phase 41 (7.1%)

Trials by Status

unknown17%
completed1071%
terminated321%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_2

Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers

NCT02348203
terminatedphase_3

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

NCT00493974
completedphase_2

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00070486
completedphase_2

Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

NCT00262405
terminatedphase_1

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

NCT01130688
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT02348203Phase 2

Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers

Completed
NCT00493974Phase 3

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

Terminated
NCT00070486Phase 2

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed
NCT00262405Phase 2

Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

Completed
NCT01130688Phase 1

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

Terminated
NCT01021215Phase 1

Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers

Completed
NCT01136941Phase 1

Trial of Zileuton CR in Children and Adults With Sickle Cell Disease

Completed
NCT01174056Early Phase 1

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

Completed
NCT00467831Phase 1

Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

Terminated
NCT00056004Phase 2

Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia

Completed
NCT00723021Phase 2

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

Completed
NCT00534625Phase 2

Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients

Completed
NCT00575861Phase 4

Zileuton and Exhaled Nitric Oxide in Asthmatics

Completed
NCT00098358Phase 2

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

Unknown

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14